Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sanjay S. Shukla
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 58
- Beta
- 0.53
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -14.10
Financials
Revenue
$0.00-100.0%Net Income
$-10.31MEBITDA
$-10.48MFree Cash Flow
$-9.42MEPS (diluted)
$-0.11Shares Outstanding (diluted)
98.07M+5694.0%Operating Expenses
$10.88MCash & Debt
$57.42MRevenue by Segment (annual)
$200.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $190.0K | $-74.12M | $-0.80 |
| 2024 | $235.0K | $-64.02M | $-0.86 |
| 2023 | $353.0K | $-50.39M | $-0.94 |
| 2022 | $10.39M | $-45.34M | $-1.60 |
| 2021 | $0.00 | $-33.77M | $-1.77 |
| 2020 | $10.46M | $-16.22M | $-1.77 |
| 2019 | $422.0K | $-23.60M | $-7.03 |
| 2018 | $0.00 | $-34.52M | $-16.13 |
| 2017 | $0.00 | $-48.21M | $-26.16 |
| 2016 | $0.00 | $-57.85M | $-34.20 |
| 2015 | $0.00 | $-47.97M | $-42.42 |
| 2014 | $0.00 | $-24.35M | $-422.73 |
| 2013 | $0.00 | $-20.01M | $-429.90 |
| 2012 | $0.00 | $-17.61M | $-0.45 |
Valuation
ATYRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
135+1250.00%Social Signal Score
Mentions (3)
- Newsbenzinga.com·22d ago·Negative
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease aTyr Pharma Inc. (NASDAQ:ATYR) secured a formal agreement with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 study protocol for its lead therapeutic candidate, efzofitimod.
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activities in the fourth quarter of 2026.
View source ↗ - Newsglobenewswire.com·45d ago·Negative
…ing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today provided an update on the expected timing of a response from the U.S. Food and Drug Administration (FDA) related to the protocol the Company…
View source ↗
Earnings
Thu, Nov 5(in 3 weeks)
Consensus estimate $-0.11 per share
Typical surprise +10.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$-0.11 vs $-0.12beat
- Fri, May 15$-0.11 vs $-0.16beat
- Thu, Mar 5$-0.14 vs $-0.18beat
- Thu, Nov 6$-0.26 vs $-0.20miss
- Thu, Aug 7$-0.22 vs $-0.18miss
- Wed, May 7$-0.17 vs $-0.19beat
Estimates and results for ATYR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ATYR officers and directors.
- Bought
- $1.3m
- Sold
- $71k
10 trades
9 trades
- Schimmel Paulbought
- Shukla Sanjaysold
- Broadfoot Jill Mariesold
- Denyes Nancysold
- Schimmel Paulbought
- Schimmel Paulbought
- Gross Jane Abought
- Broadfoot Jill Mariesold
42 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ATYR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.